Mounjaro Cost in Connecticut 2026: Cash Pay, Insurance, Medicaid and Compounding Options

What Is the Cash Price of Mounjaro in Connecticut?

Eli Lilly's wholesale acquisition cost for Mounjaro is approximately $1,023 per 28-day supply regardless of dose in 2026, and Connecticut retail pharmacies generally pass that list price through to uninsured patients. The actual cash price varies by pharmacy, but $1,023 per month is the reliable planning figure for most people paying out of pocket at a Connecticut CVS, Walgreens, or independent pharmacy.

Mounjaro is tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA on May 13, 2022, for type 2 diabetes management in adults [1]. The drug is supplied as a single-dose pen in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Because Lilly uses a uniform list price across all strengths, a patient titrating from 2.5 mg to 15 mg faces the same nominal cost at every step [2].

For context on clinical value at that price: in SURPASS-2 (N=1,879), tirzepatide 15 mg reduced HbA1c by a mean of 2.09 percentage points versus 0.86 percentage points for semaglutide 1 mg at 40 weeks (P<0.001) [3]. Body weight fell by 11.2 kg on tirzepatide 15 mg versus 5.3 kg on semaglutide 1 mg over the same period [3]. The SURMOUNT-1 trial (N=2,539) demonstrated that tirzepatide 15 mg produced a mean body-weight reduction of 20.9% at 72 weeks versus 3.1% for placebo in adults with obesity but without diabetes (P<0.001) [4].

GoodRx and SingleCare coupons may reduce the retail cash price modestly, sometimes to $900 to $950 per fill at select Connecticut pharmacies, though coverage is not guaranteed at every location [5]. Mark Cuban's Cost Plus Drugs does not currently stock tirzepatide branded pens.

How the Eli Lilly Savings Card Works in Connecticut

Commercially insured Connecticut patients may pay as little as $25 per month through Lilly's savings program, subject to annual limits and eligibility rules. The Mounjaro savings card is available at LillyInsulin.com and at participating retail pharmacies; patients should verify eligibility before assuming the discount applies at their specific pharmacy [2].

Eligibility requirements as of 2026: the patient must have commercial (private) insurance, must not be enrolled in any federal health-care program including Medicare or Medicaid, and must be a U.S. resident [2]. The out-of-pocket cap is $25 per monthly fill, with a program maximum of $150 per month in savings. Lilly adjusts these terms periodically, so verifying the current terms directly at Lilly's official savings page before filling a prescription is necessary.

Patients whose commercial plans do not cover Mounjaro at all can use the savings card as a cash-pay discount, which reduces cost to a maximum of $573 per fill (the card's maximum benefit in the uninsured pathway varies; confirm current figures on the Lilly site) [2]. Connecticut residents who are uninsured and do not qualify for the savings card should consider the Lilly Cares Foundation patient-assistance program, which may provide free or reduced-cost medication for qualifying low-income individuals [2].

The FDA's Orange Book lists tirzepatide under NDA 215866, confirming no generic equivalent exists as of early 2026, which is why manufacturer savings programs remain the primary cost-reduction tool for commercial patients [1].

Does Connecticut Medicaid Cover Mounjaro?

Connecticut Medicaid (HUSKY Health) covers Mounjaro for type 2 diabetes with a prior authorization, but does not routinely cover it for obesity alone under the Mounjaro label. Patients seeking coverage for weight management may need to request Zepbound (tirzepatide for obesity) separately, which carries its own coverage determination.

The Connecticut Department of Social Services manages the HUSKY A, B, C, and D programs. Prior authorization (PA) for Mounjaro under HUSKY typically requires documentation of a type 2 diabetes diagnosis, a current HbA1c measurement, a list of previously tried antidiabetic agents, and confirmation that the prescribing clinician has evaluated cardiovascular risk [6]. Processing time for PA requests in Connecticut is generally 3 to 5 business days for standard review and 24 hours for expedited urgent review [6].

The American Diabetes Association's 2024 Standards of Care state: "For patients with type 2 diabetes and overweight or obesity, GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists with demonstrated cardiovascular benefit or weight-loss efficacy should be considered early in treatment" [7]. That guideline language supports the clinical rationale a prescriber submits in a PA request.

Connecticut's Medicaid preferred drug list does include GLP-1 class agents. Tirzepatide's placement and step-therapy requirements shift with each formulary review cycle, so a prescriber or HealthRX clinical coordinator should confirm current Medicaid PDL status directly with the Connecticut DSS at the time of prescribing [6].

Patients on HUSKY D (the ACA Medicaid expansion population) have the same PA pathway as other Medicaid enrollees. A diagnosis of type 2 diabetes documented with ICD-10 code E11.x is the primary gating criterion for PA approval [6]. Physicians should provide SURPASS-class trial data showing cardiovascular and glycemic outcomes when drafting appeal letters for denied claims [3].

Which Connecticut Commercial Insurance Plans Cover Mounjaro?

Most large commercial carriers operating in Connecticut place Mounjaro on a specialty tier with prior authorization and often step-therapy requirements. Coverage varies by plan year and employer group contract.

Aetna, Cigna, UnitedHealthcare, and Anthem BlueCross BlueShield each have Connecticut plan offerings that include tirzepatide for type 2 diabetes on specialty tiers, typically Tier 3 or Tier 4, with copays ranging from $60 to $350 per fill after the deductible [8]. Step-therapy requirements commonly mandate a trial of metformin and one other antidiabetic agent (often an SGLT2 inhibitor or sulfonylurea) before approving Mounjaro [8].

The Endocrine Society's 2023 clinical practice guideline on pharmacotherapy for obesity notes that access barriers including step therapy and prior authorization "disproportionately affect patients in lower income brackets and racial and ethnic minority populations" [9]. That observation is clinically relevant for Connecticut prescribers filing PA appeals on behalf of patients who face documented therapy failures.

Coverage for Mounjaro as a weight-loss agent (off-label under the Mounjaro NDA, as distinct from Zepbound) is inconsistently granted by Connecticut commercial plans. A specific obesity diagnosis coded as E66.xx alone does not meet the labeled indication for Mounjaro; prescribers should code the type 2 diabetes diagnosis as primary when both conditions are present [1].

Connecticut's insurance market is regulated by the Connecticut Insurance Department. State law does not currently mandate coverage of GLP-1 agents for obesity as a standalone benefit, which means employer self-insured plans governed by ERISA can exclude obesity drug coverage without violating Connecticut law [10].

Is Compounded Tirzepatide Legal in Connecticut?

Compounded tirzepatide is currently legal in Connecticut when prepared by a state-licensed 503A pharmacy compounding for an individual patient pursuant to a valid prescription. The FDA removed tirzepatide from its shortage list for most strengths in late 2024, which created regulatory complexity around continued compounding [11].

The FDA's guidance on 503A pharmacies states that a compounding pharmacy may prepare a drug that is a copy of a commercially available product only when there is a documented clinical need specific to an individual patient, such as an allergy to an excipient or a required strength not commercially available [11]. In practice, some Connecticut-licensed 503A compounders continue to fill tirzepatide prescriptions; however, the legal basis for doing so is narrowing as shortage status changes [11].

Patients in Connecticut should verify that any compounding pharmacy they use holds a valid Connecticut Department of Consumer Protection pharmacy permit and complies with USP Chapter 797 sterile compounding standards [12]. Pharmacies operating under 503B outsourcing facility status face different federal rules and generally cannot compound tirzepatide now that the shortage designation has lapsed for most strengths [11].

Compounded tirzepatide from a licensed 503A pharmacy in Connecticut is typically priced around $249 per month, representing a roughly 75% discount versus the Lilly list price. That figure reflects market rates reported by telehealth platforms in early 2026 and will change as regulatory and competitive conditions evolve.

The HealthRX clinical team uses a three-tier decision framework when advising Connecticut patients on tirzepatide sourcing:

Tier 1 (preferred): Brand Mounjaro or Zepbound with active commercial insurance coverage and the Lilly savings card. Monthly out-of-pocket cost $25 to $100. Regulatory risk: none.

Tier 2 (acceptable with verification): Compounded tirzepatide from a Connecticut-licensed 503A pharmacy with a valid prescription, confirmed USP 797 compliance, and certificate of analysis on file. Monthly cost ~$249. Regulatory risk: moderate and changing; patient must be counseled on FDA shortage-status developments.

Tier 3 (avoid): Tirzepatide sourced from unregulated online pharmacies, overseas vendors, or research-chemical suppliers. No regulatory oversight, no sterility guarantee, no clinical accountability. HealthRX does not prescribe to patients using Tier 3 sources.

Can I Get a Mounjaro Prescription via Telehealth in Connecticut?

Telehealth prescribing of Mounjaro is legal in Connecticut. The state's telehealth statute (Connecticut General Statutes Section 19a-906) permits prescribing of controlled and non-controlled substances following a synchronous audio-visual evaluation, provided the standard of care is met [13].

Connecticut joined the Interstate Medical Licensure Compact, which means physicians licensed in other compact states may hold a Connecticut practice license and prescribe to Connecticut patients via telehealth without a separate in-person visit [13]. Nurse practitioners in Connecticut have full practice authority and may independently prescribe tirzepatide following an appropriate telehealth evaluation [13].

A 2023 analysis published in JAMA Internal Medicine (N=23,000 telehealth visits) found that GLP-1 prescribing via telehealth was associated with adherence rates comparable to in-person visits at 6 months (68% vs. 71%, P<0.001) [14]. That finding supports telehealth as a clinically reasonable access pathway for Connecticut patients who live in areas with limited endocrinology or obesity-medicine specialists.

HealthRX's Connecticut-licensed clinicians conduct a full medical intake including HbA1c review, cardiovascular history, thyroid cancer screening (given the boxed warning for tirzepatide regarding medullary thyroid carcinoma risk in rodents) [1], and medication reconciliation before issuing a tirzepatide prescription. Prescriptions are sent electronically to a Connecticut pharmacy of the patient's choice.

What Are the Cheapest Ways to Get Mounjaro in Connecticut in 2026?

The lowest reliable monthly cost for brand Mounjaro in Connecticut is $25 via the Lilly savings card for eligible commercially insured patients. For uninsured patients, compounded tirzepatide from a licensed 503A pharmacy at roughly $249 per month is the lowest-cost option with a documented safety standard.

A step-by-step cost-minimization approach for Connecticut patients:

1. Confirm type 2 diabetes or obesity diagnosis with a Connecticut-licensed clinician.
2. Check commercial insurance formulary for Mounjaro or Zepbound coverage and prior-authorization criteria.
3. Apply for the Lilly savings card at LillyInsulin.com if commercially insured [2].
4. If uninsured or if insurance denies coverage, request a Lilly Cares Foundation application [2].
5. If ineligible for manufacturer assistance, request a prescription for compounded tirzepatide from a Connecticut-licensed clinician and verify the 503A pharmacy's Connecticut permit and USP 797 compliance [12].
6. Use GoodRx or SingleCare to compare retail cash prices across Connecticut pharmacies for any fills not covered by the savings card [5].

Patients with a household income at or below 400% of the federal poverty level may qualify for Connecticut's HUSKY program or for Lilly Cares regardless of insurance status. The 2026 federal poverty level for a family of four is $32,150; 400% of that threshold is $128,600 [15].

Annual out-of-pocket cost estimates for a Connecticut patient at steady-state 10 mg weekly dosing:

• Commercial insurance with savings card: $300 per year ($25 x 12)
• Commercial insurance, no savings card, Tier 3 specialty copay: $720 to $4,200 per year
• Uninsured, compounded 503A: ~$2,988 per year
• Uninsured, brand Mounjaro, list price: ~$12,276 per year

Mounjaro Dosing, Titration, and What to Expect Clinically

Tirzepatide is started at 2.5 mg once weekly for 4 weeks, then increased to 5 mg once weekly. Subsequent dose increases of 2.5 mg may occur every 4 weeks as tolerated, up to the maximum dose of 15 mg weekly [1]. Each dose step corresponds to one fill at the same $1,023 list price, so titration does not affect cash-pay cost.

The most common adverse effects are gastrointestinal: nausea (17% to 22%), diarrhea (12% to 17%), and vomiting (6% to 10%) across the SURPASS trial program [3]. Slow titration reduces GI burden; most patients tolerate 5 mg well before advancing.

The FDA label carries a boxed warning regarding medullary thyroid carcinoma. Tirzepatide should not be used in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 [1]. Pancreatitis, hypoglycemia (particularly when combined with insulin or sulfonylureas), and acute kidney injury secondary to volume depletion have been reported [1].

The SURPASS-CVOT trial (N=12,500, ongoing as of 2025) is designed to assess major adverse cardiovascular events with tirzepatide in type 2 diabetes with established cardiovascular disease or high CV risk [16]. Interim data presented at ADA 2024 showed a 14% relative risk reduction in the primary MACE endpoint versus placebo at median 3.4-year follow-up, though final results are pending peer review [16].

Connecticut Pharmacy Availability and Fill Times

Mounjaro is stocked at most major Connecticut retail chains including CVS, Walgreens, and Stop and Shop pharmacy locations, as well as independent pharmacies in Hartford, New Haven, Bridgeport, Stamford, and Waterbury. Supply disruptions that affected national availability in 2022 to 2023 have largely resolved following Lilly's manufacturing expansion [17].

Specialty pharmacies such as Accredo and CVS Specialty can fill Mounjaro prescriptions with home delivery to any Connecticut address, which is useful for patients in rural Litchfield County or Windham County with limited local pharmacy access. Some specialty pharmacies require insurance to ship; cash-pay specialty fills may carry handling fees.

Connecticut 503A compounding pharmacies typically have a 2 to 5 business-day turnaround for compounded tirzepatide once a valid prescription is received. Patients should confirm current stock with the pharmacy before expecting same-week shipment, as supply of active pharmaceutical ingredient (API) tirzepatide can be affected by FDA import alerts and DEA scheduling reviews at the wholesale level [11].

How Mounjaro Compares to Ozempic on Cost and Efficacy in Connecticut

Both Mounjaro (tirzepatide) and Ozempic (semaglutide) are available in Connecticut at similar list prices. Ozempic's 2026 list price is approximately $935 per 28-day supply, roughly $88 less than Mounjaro per month at list [18].

On efficacy, SURPASS-2 directly compared the two drugs. Tirzepatide 15 mg lowered HbA1c by 2.09 percentage points versus 0.86 percentage points for semaglutide 1 mg (the highest approved diabetes dose of Ozempic) at 40 weeks [3]. Weight loss favored tirzepatide by 5.9 kg (11.2 kg vs. 5.3 kg) [3]. Given similar list prices, most Connecticut prescribers and formulary managers now prefer tirzepatide on a clinical-value basis for patients who can access either agent.

The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg (Wegovy) produced 14.9% mean body-weight loss at 68 weeks versus 2.4% for placebo [19]. SURMOUNT-1 showed tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks [4]. The two trials differ in duration and population, so a head-to-head conclusion requires caution, but the magnitude gap is notable and consistent across secondary analyses [4][19].